window.protocolData = window.protocolData || {};
window.protocolData.leukemia = {
  "cml": {
    "primary_treatment": {
      "Imatinib-First-Line": {
        "name": "Imatinib (IRIS) (BCR-ABL TKI)",
        "drugs": [
          {
            "name": "Imatinib",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Dasatinib-First-Line": {
        "name": "Dasatinib (DASISION) (BCR-ABL TKI)",
        "drugs": [
          {
            "name": "Dasatinib",
            "dose": 100,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Nilotinib-First-Line": {
        "name": "Nilotinib (ENESTnd) (BCR-ABL TKI)",
        "drugs": [
          {
            "name": "Nilotinib",
            "dose": 300,
            "unit": "mg",
            "schedule": "PO twice daily continuously"
          }
        ]
      },
      "Bosutinib-First-Line": {
        "name": "Bosutinib (BFORE) (BCR-ABL TKI)",
        "drugs": [
          {
            "name": "Bosutinib",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Dasatinib-Second-Line": {
        "name": "Dasatinib (BCR-ABL TKI) (chronic phase, 2nd line)",
        "drugs": [
          {
            "name": "Dasatinib",
            "dose": 100,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Dasatinib-AP-BP": {
        "name": "Dasatinib (BCR-ABL TKI) (accelerated/blast phase)",
        "drugs": [
          {
            "name": "Dasatinib",
            "dose": 140,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Nilotinib-Second-Line": {
        "name": "Nilotinib (BCR-ABL TKI) (2nd line)",
        "drugs": [
          {
            "name": "Nilotinib",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO twice daily continuously"
          }
        ]
      },
      "Bosutinib-Second-Line": {
        "name": "Bosutinib (BCR-ABL TKI) (2nd/3rd line)",
        "drugs": [
          {
            "name": "Bosutinib",
            "dose": 500,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Ponatinib": {
        "name": "Ponatinib (PACE) (BCR-ABL TKI) (T315I/multi-TKI resistant)",
        "drugs": [
          {
            "name": "Ponatinib",
            "dose": 45,
            "unit": "mg",
            "schedule": "PO once daily continuously (reduce to 30mg or 15mg based on response)"
          }
        ]
      },
      "Asciminib-First-Line": {
        "name": "Asciminib (ASC4FIRST) (STAMP inhibitor) (1st line CML-CP)",
        "drugs": [
          {
            "name": "Asciminib",
            "dose": 60,
            "unit": "mg",
            "schedule": "PO twice daily continuously"
          }
        ]
      },
      "Asciminib-T315I": {
        "name": "Asciminib (ASCEMBL) (STAMP inhibitor) (T315I mutation)",
        "drugs": [
          {
            "name": "Asciminib",
            "dose": 200,
            "unit": "mg",
            "schedule": "PO twice daily continuously"
          }
        ]
      },
      "Asciminib-Non-T315I": {
        "name": "Asciminib (ASCEMBL) (STAMP inhibitor) (non-T315I, ≥3rd line)",
        "drugs": [
          {
            "name": "Asciminib",
            "dose": 40,
            "unit": "mg",
            "schedule": "PO twice daily continuously"
          }
        ]
      },
      "Omacetaxine": {
        "name": "Omacetaxine (protein synthesis inhibitor) (T315I/multi-TKI failure)",
        "drugs": [
          {
            "name": "Omacetaxine",
            "dose": 1.25,
            "unit": "mg/m²",
            "schedule": "SC twice daily D1-14, every 28 days"
          }
        ]
      },
      "Imatinib-High-Dose": {
        "name": "Imatinib high-dose (BCR-ABL TKI) (blast crisis)",
        "drugs": [
          {
            "name": "Imatinib",
            "dose": 600,
            "unit": "mg",
            "schedule": "PO once daily continuously (may increase to 800mg)"
          }
        ]
      },
      "Hydroxyurea": {
        "name": "Hydroxyurea (cytoreductive therapy) (initial cytoreduction/bridge)",
        "drugs": [
          {
            "name": "Hydroxyurea",
            "dose": 1000,
            "unit": "mg",
            "schedule": "PO twice daily (titrate 500-3000mg daily based on counts)"
          }
        ]
      },
      "Interferon-alpha-2a": {
        "name": "Interferon alpha-2a (pregnancy/TKI-intolerant/special circumstances)",
        "drugs": [
          {
            "name": "Interferon alpha-2a",
            "dose": 5,
            "unit": "MIU",
            "schedule": "SC daily continuously"
          }
        ]
      }
    }
  },
  "cll": {
    "primary_treatment": {
      "Ibrutinib-Monotherapy": {
        "name": "Ibrutinib (RESONATE-2) (BTK inhibitor)",
        "drugs": [
          {
            "name": "Ibrutinib",
            "dose": 420,
            "unit": "mg",
            "schedule": "PO once daily continuously until progression"
          }
        ]
      },
      "Acalabrutinib-Monotherapy": {
        "name": "Acalabrutinib (ELEVATE-TN) (BTK inhibitor)",
        "drugs": [
          {
            "name": "Acalabrutinib",
            "dose": 100,
            "unit": "mg",
            "schedule": "PO twice daily continuously until progression"
          }
        ]
      },
      "Zanubrutinib-Monotherapy": {
        "name": "Zanubrutinib (ALPINE) (BTK inhibitor)",
        "drugs": [
          {
            "name": "Zanubrutinib",
            "dose": 160,
            "unit": "mg",
            "schedule": "PO twice daily continuously until progression"
          }
        ]
      },
      "Venetoclax-Obinutuzumab": {
        "name": "Venetoclax + Obinutuzumab (CLL14) (BCL-2 + anti-CD20)",
        "drugs": [
          {
            "name": "Venetoclax",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily (5-week ramp-up), cycles 1-12"
          },
          {
            "name": "Obinutuzumab",
            "dose": 1000,
            "unit": "mg",
            "schedule": "D1,8,15 cycle 1, then D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "Acalabrutinib-Obinutuzumab": {
        "name": "Acalabrutinib + Obinutuzumab (ELEVATE-TN) (BTK + anti-CD20)",
        "drugs": [
          {
            "name": "Acalabrutinib",
            "dose": 100,
            "unit": "mg",
            "schedule": "PO twice daily continuously until progression"
          },
          {
            "name": "Obinutuzumab",
            "dose": 1000,
            "unit": "mg",
            "schedule": "D1,8,15 cycle 1, then D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "Ibrutinib-Obinutuzumab": {
        "name": "Ibrutinib + Obinutuzumab (iLLUMINATE) (BTK + anti-CD20)",
        "drugs": [
          {
            "name": "Ibrutinib",
            "dose": 420,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          },
          {
            "name": "Obinutuzumab",
            "dose": 1000,
            "unit": "mg",
            "schedule": "D1,8,15 cycle 1, then D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "FCR": {
        "name": "FCR (CLL8) (fludarabine + cyclophosphamide + rituximab)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Fludarabine",
            "dose": 25,
            "unit": "mg/m²",
            "schedule": "IV D1-3, every 28 days"
          },
          {
            "name": "Cyclophosphamide",
            "dose": 250,
            "unit": "mg/m²",
            "schedule": "IV D1-3, every 28 days"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "D1 cycle 1 (375mg/m²), then 500mg/m² D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "BR": {
        "name": "BR (MABLE) (bendamustine + rituximab)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Bendamustine",
            "dose": 90,
            "unit": "mg/m²",
            "schedule": "IV D1-2, every 28 days"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "D1 cycle 1 (375mg/m²), then 500mg/m² D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "Chlorambucil-Obinutuzumab": {
        "name": "Chlorambucil + Obinutuzumab (CLL11) (alkylator + anti-CD20)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Chlorambucil",
            "dose": 0.5,
            "unit": "mg/kg",
            "schedule": "PO D1,15, every 28 days"
          },
          {
            "name": "Obinutuzumab",
            "dose": 1000,
            "unit": "mg",
            "schedule": "D1,8,15 cycle 1, then D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "Ibrutinib-Venetoclax": {
        "name": "Ibrutinib + Venetoclax (GLOW) (BTK + BCL-2)",
        "drugs": [
          {
            "name": "Ibrutinib",
            "dose": 420,
            "unit": "mg",
            "schedule": "PO once daily, cycles 1-15"
          },
          {
            "name": "Venetoclax",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily (5-week ramp-up), cycles 4-15"
          }
        ]
      },
      "Venetoclax-Rituximab-Frontline": {
        "name": "Venetoclax + Rituximab (BCL-2 + anti-CD20) (frontline)",
        "drugs": [
          {
            "name": "Venetoclax",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily (5-week ramp-up), 24 months"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "D1 cycle 1 (375mg/m²), then 500mg/m² D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "Chlorambucil-Monotherapy": {
        "name": "Chlorambucil monotherapy (elderly/comorbid)",
        "cycles": 12,
        "drugs": [
          {
            "name": "Chlorambucil",
            "dose": 0.5,
            "unit": "mg/kg",
            "schedule": "PO D1,15, every 28 days"
          }
        ]
      }
    },
    "relapsed_refractory": {
      "Ibrutinib-RR": {
        "name": "Ibrutinib (RESONATE) (BTK inhibitor)",
        "drugs": [
          {
            "name": "Ibrutinib",
            "dose": 420,
            "unit": "mg",
            "schedule": "PO once daily continuously until progression"
          }
        ]
      },
      "Acalabrutinib-RR": {
        "name": "Acalabrutinib (ACE-CL-001) (BTK inhibitor)",
        "drugs": [
          {
            "name": "Acalabrutinib",
            "dose": 100,
            "unit": "mg",
            "schedule": "PO twice daily continuously until progression"
          }
        ]
      },
      "Zanubrutinib-RR": {
        "name": "Zanubrutinib (ALPINE) (BTK inhibitor)",
        "drugs": [
          {
            "name": "Zanubrutinib",
            "dose": 160,
            "unit": "mg",
            "schedule": "PO twice daily continuously until progression"
          }
        ]
      },
      "Venetoclax-Rituximab-RR": {
        "name": "Venetoclax + Rituximab (MURANO) (BCL-2 + anti-CD20)",
        "drugs": [
          {
            "name": "Venetoclax",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily (5-week ramp-up), 24 months"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "D1 cycle 1 (375mg/m²), then 500mg/m² D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "Venetoclax-Monotherapy-RR": {
        "name": "Venetoclax monotherapy (BCL-2 inhibitor) (del17p/TP53)",
        "drugs": [
          {
            "name": "Venetoclax",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily (5-week ramp-up) continuously until progression"
          }
        ]
      },
      "Idelalisib-Rituximab": {
        "name": "Idelalisib + Rituximab (Study 116) (PI3Kδ + anti-CD20)",
        "drugs": [
          {
            "name": "Idelalisib",
            "dose": 150,
            "unit": "mg",
            "schedule": "PO twice daily continuously"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "D1 then 500mg/m² every 14 days x 4, then every 28 days x 3"
          }
        ]
      },
      "Lisocabtagene-Maraleucel-RR": {
        "name": "Lisocabtagene maraleucel (TRANSCEND CLL 004) (CAR-T anti-CD19) (post-BTKi + BCL-2i)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Lisocabtagene maraleucel",
            "dose": 100,
            "unit": "× 10⁶ CAR+ T cells",
            "schedule": "Single IV infusion (50 × 10⁶ CD8+ and 50 × 10⁶ CD4+ CAR+ T cells)"
          }
        ]
      },
      "Pirtobrutinib": {
        "name": "Pirtobrutinib (BRUIN) (non-covalent BTK inhibitor) (post-covalent BTKi)",
        "drugs": [
          {
            "name": "Pirtobrutinib",
            "dose": 200,
            "unit": "mg",
            "schedule": "PO once daily continuously until progression"
          }
        ]
      },
      "FCR-RR": {
        "name": "FCR (fludarabine + cyclophosphamide + rituximab) (R/R)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Fludarabine",
            "dose": 25,
            "unit": "mg/m²",
            "schedule": "IV D1-3, every 28 days"
          },
          {
            "name": "Cyclophosphamide",
            "dose": 250,
            "unit": "mg/m²",
            "schedule": "IV D1-3, every 28 days"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "D1 cycle 1 (375mg/m²), then 500mg/m² D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "BR-RR": {
        "name": "Bendamustine + Rituximab (R/R)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Bendamustine",
            "dose": 70,
            "unit": "mg/m²",
            "schedule": "IV D1-2, every 28 days"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "D1 cycle 1 (375mg/m²), then 500mg/m² D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "Ibrutinib-Venetoclax-RR": {
        "name": "Ibrutinib + Venetoclax (BTK + BCL-2) (R/R)",
        "drugs": [
          {
            "name": "Ibrutinib",
            "dose": 420,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          },
          {
            "name": "Venetoclax",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily (5-week ramp-up) continuously"
          }
        ]
      },
      "Ofatumumab-RR": {
        "name": "Ofatumumab monotherapy (anti-CD20) (fludarabine-refractory)",
        "drugs": [
          {
            "name": "Ofatumumab",
            "dose": 300,
            "unit": "mg",
            "schedule": "IV D1, then 2000mg weekly x 7, then monthly x 4"
          }
        ]
      },
      "Obinutuzumab-Monotherapy-RR": {
        "name": "Obinutuzumab monotherapy (anti-CD20) (R/R)",
        "drugs": [
          {
            "name": "Obinutuzumab",
            "dose": 1000,
            "unit": "mg",
            "schedule": "D1,8,15 cycle 1, then D1 cycles 2-6, every 28 days"
          }
        ]
      },
      "Lenalidomide-Rituximab-RR": {
        "name": "Lenalidomide + Rituximab (CONTINUUM) (IMiD + anti-CD20)",
        "drugs": [
          {
            "name": "Lenalidomide",
            "dose": 20,
            "unit": "mg",
            "schedule": "PO D1-21, every 28 days"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "D1, every 28 days"
          }
        ]
      }
    }
  },
  "hcl": {
    "primary_treatment": {
      "Cladribine-IV": {
        "name": "Cladribine IV (2-CdA) (purine analog)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Cladribine",
            "dose": 0.09,
            "unit": "mg/kg",
            "schedule": "CIV over 7 days (single course)"
          }
        ]
      },
      "Cladribine-SC": {
        "name": "Cladribine SC (2-CdA) (purine analog)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Cladribine",
            "dose": 0.14,
            "unit": "mg/kg",
            "schedule": "SC daily D1-5 (single course)"
          }
        ]
      },
      "Pentostatin": {
        "name": "Pentostatin (deoxycoformycin) (purine analog)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Pentostatin",
            "dose": 4,
            "unit": "mg/m²",
            "schedule": "IV D1, every 14 days for 3-6 months"
          }
        ]
      },
      "Cladribine-Rituximab": {
        "name": "Cladribine + Rituximab (purine analog + anti-CD20)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Cladribine",
            "dose": 0.09,
            "unit": "mg/kg",
            "schedule": "CIV over 7 days (single course)"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "Weekly x 8 doses (starting 1 month after cladribine)"
          }
        ]
      },
      "Interferon-alpha-HCL": {
        "name": "Interferon alpha-2a (pregnancy/unable to receive purine analogs)",
        "drugs": [
          {
            "name": "Interferon alpha-2a",
            "dose": 3,
            "unit": "MIU",
            "schedule": "SC three times weekly continuously"
          }
        ]
      }
    },
    "relapsed_refractory": {
      "Cladribine-Retreatment": {
        "name": "Cladribine retreatment (2-CdA) (purine analog)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Cladribine",
            "dose": 0.09,
            "unit": "mg/kg",
            "schedule": "CIV over 7 days (single course)"
          }
        ]
      },
      "Pentostatin-Retreatment": {
        "name": "Pentostatin retreatment (purine analog)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Pentostatin",
            "dose": 4,
            "unit": "mg/m²",
            "schedule": "IV D1, every 14 days"
          }
        ]
      },
      "Rituximab-HCL-RR": {
        "name": "Rituximab monotherapy (anti-CD20) (R/R HCL)",
        "drugs": [
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "Weekly x 4-8 doses"
          }
        ]
      },
      "Vemurafenib-HCL": {
        "name": "Vemurafenib (BRAF V600E inhibitor) (R/R HCL)",
        "drugs": [
          {
            "name": "Vemurafenib",
            "dose": 960,
            "unit": "mg",
            "schedule": "PO twice daily for 16-18 weeks"
          }
        ]
      },
      "Vemurafenib-Rituximab-HCL": {
        "name": "Vemurafenib + Rituximab (BRAF V600E + anti-CD20) (R/R HCL)",
        "drugs": [
          {
            "name": "Vemurafenib",
            "dose": 960,
            "unit": "mg",
            "schedule": "PO twice daily for 16 weeks"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "Every 14 days x 8 doses (starting week 5)"
          }
        ]
      },
      "Bendamustine-Rituximab-HCL": {
        "name": "Bendamustine + Rituximab (alkylator + anti-CD20) (R/R HCL)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Bendamustine",
            "dose": 70,
            "unit": "mg/m²",
            "schedule": "IV D1-2, every 28 days"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "D1, every 28 days"
          }
        ]
      },
      "Interferon-alpha-HCL-RR": {
        "name": "Interferon alpha-2a (R/R HCL, unable to receive purine analogs)",
        "drugs": [
          {
            "name": "Interferon alpha-2a",
            "dose": 3,
            "unit": "MIU",
            "schedule": "SC three times weekly continuously"
          }
        ]
      },
      "Cladribine-Rituximab-RR": {
        "name": "Cladribine + Rituximab (purine analog + anti-CD20) (R/R)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Cladribine",
            "dose": 0.09,
            "unit": "mg/kg",
            "schedule": "CIV over 7 days (single course)"
          },
          {
            "name": "Rituximab",
            "dose": 375,
            "unit": "mg/m²",
            "schedule": "Weekly x 8 doses (starting 1 month after cladribine)"
          }
        ]
      }
    }
  },
  "all": {
    "primary_treatment": {
      "HyperCVAD": {
        "name": "Hyper-CVAD (MDACC) (intensive, alternating cycles)",
        "cycles": 8,
        "drugs": [
          {
            "name": "Cyclophosphamide",
            "dose": 300,
            "unit": "mg/m²",
            "schedule": "IV q12h D1-3 (6 doses), odd cycles"
          },
          {
            "name": "Vincristine",
            "dose": 2,
            "unit": "mg",
            "schedule": "IV D4,11, odd cycles"
          },
          {
            "name": "Doxorubicin",
            "dose": 50,
            "unit": "mg/m²",
            "schedule": "CIV over 24h D4, odd cycles"
          },
          {
            "name": "Dexamethasone",
            "dose": 40,
            "unit": "mg",
            "schedule": "PO/IV D1-4, D11-14, odd cycles"
          },
          {
            "name": "Methotrexate",
            "dose": 200,
            "unit": "mg/m²",
            "schedule": "IV over 2h then 800mg/m² over 22h D1, even cycles"
          },
          {
            "name": "Cytarabine",
            "dose": 3000,
            "unit": "mg/m²",
            "schedule": "IV q12h D2-3 (4 doses), even cycles"
          }
        ]
      },
      "BFM-95": {
        "name": "ALL-BFM 95 (Protocol I induction) (pediatric/AYA)",
        "drugs": [
          {
            "name": "Prednisone",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "PO daily D1-28, then taper D29-36"
          },
          {
            "name": "Vincristine",
            "dose": 1.5,
            "unit": "mg/m²",
            "schedule": "IV D8,15,22,29 (max 2mg)"
          },
          {
            "name": "Daunorubicin",
            "dose": 30,
            "unit": "mg/m²",
            "schedule": "IV D8,15,22,29"
          },
          {
            "name": "L-Asparaginase",
            "dose": 10000,
            "unit": "IU/m²",
            "schedule": "IV/IM D12,15,18,21,24,27,30,33 (8 doses)"
          },
          {
            "name": "Cyclophosphamide",
            "dose": 1000,
            "unit": "mg/m²",
            "schedule": "IV D36,64"
          },
          {
            "name": "Cytarabine",
            "dose": 75,
            "unit": "mg/m²",
            "schedule": "IV D38-41, 45-48, 52-55, 59-62"
          },
          {
            "name": "6-Mercaptopurine",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "PO daily D36-63"
          }
        ]
      },
      "CALGB-10403-AYA": {
        "name": "CALGB 10403 (AYA protocol, age 15-39)",
        "drugs": [
          {
            "name": "Daunorubicin",
            "dose": 25,
            "unit": "mg/m²",
            "schedule": "IV D1,8,15,22 (induction)"
          },
          {
            "name": "Vincristine",
            "dose": 1.5,
            "unit": "mg/m²",
            "schedule": "IV D1,8,15,22 (induction)"
          },
          {
            "name": "Prednisone",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "PO daily D1-28 (induction)"
          },
          {
            "name": "PEG-Asparaginase",
            "dose": 2500,
            "unit": "IU/m²",
            "schedule": "IM D5,22 (induction)"
          }
        ]
      },
      "GRAALL-2005": {
        "name": "GRAALL-2005 (adult ALL intensive induction)",
        "drugs": [
          {
            "name": "Daunorubicin",
            "dose": 50,
            "unit": "mg/m²",
            "schedule": "IV D1-3 (induction)"
          },
          {
            "name": "Vincristine",
            "dose": 2,
            "unit": "mg",
            "schedule": "IV D1,8,15,22 (induction)"
          },
          {
            "name": "Prednisone",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "PO daily D1-21 (induction)"
          },
          {
            "name": "Cyclophosphamide",
            "dose": 750,
            "unit": "mg/m²",
            "schedule": "IV D1,15 (induction)"
          },
          {
            "name": "PEG-Asparaginase",
            "dose": 2500,
            "unit": "IU/m²",
            "schedule": "IM D1 (induction)"
          }
        ]
      },
      "Imatinib-MultiAgent-PhPos": {
        "name": "Imatinib + multi-agent chemotherapy (UKALL12/ECOG2993) (Ph+ ALL)",
        "cycles": 8,
        "drugs": [
          {
            "name": "Imatinib",
            "dose": 600,
            "unit": "mg",
            "schedule": "PO daily continuously (concurrent with each chemo phase)"
          },
          {
            "name": "Daunorubicin",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "IV D1-3 (induction)"
          },
          {
            "name": "Vincristine",
            "dose": 1.5,
            "unit": "mg/m²",
            "schedule": "IV D1,8,15,22 (induction)"
          },
          {
            "name": "Prednisone",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "PO daily D1-28 (induction)"
          },
          {
            "name": "L-Asparaginase",
            "dose": 6000,
            "unit": "IU/m²",
            "schedule": "IM D5,8,11,15,18,22 (induction)"
          }
        ]
      },
      "Dasatinib-HyperCVAD-PhPos": {
        "name": "Dasatinib + Hyper-CVAD (Ph+ ALL)",
        "cycles": 8,
        "drugs": [
          {
            "name": "Dasatinib",
            "dose": 140,
            "unit": "mg",
            "schedule": "PO daily continuously D1-14 of each cycle"
          },
          {
            "name": "Cyclophosphamide",
            "dose": 300,
            "unit": "mg/m²",
            "schedule": "IV q12h D1-3 (6 doses), odd cycles"
          },
          {
            "name": "Vincristine",
            "dose": 2,
            "unit": "mg",
            "schedule": "IV D4,11, odd cycles"
          },
          {
            "name": "Doxorubicin",
            "dose": 50,
            "unit": "mg/m²",
            "schedule": "CIV over 24h D4, odd cycles"
          },
          {
            "name": "Dexamethasone",
            "dose": 40,
            "unit": "mg",
            "schedule": "PO/IV D1-4, D11-14, odd cycles"
          }
        ]
      },
      "Ponatinib-HyperCVAD-PhPos": {
        "name": "Ponatinib + Hyper-CVAD (Ph+ ALL)",
        "cycles": 8,
        "drugs": [
          {
            "name": "Ponatinib",
            "dose": 45,
            "unit": "mg",
            "schedule": "PO daily continuously (reduce to 30mg after CR)"
          },
          {
            "name": "Cyclophosphamide",
            "dose": 300,
            "unit": "mg/m²",
            "schedule": "IV q12h D1-3 (6 doses), odd cycles"
          },
          {
            "name": "Vincristine",
            "dose": 2,
            "unit": "mg",
            "schedule": "IV D4,11, odd cycles"
          },
          {
            "name": "Doxorubicin",
            "dose": 50,
            "unit": "mg/m²",
            "schedule": "CIV over 24h D4, odd cycles"
          },
          {
            "name": "Dexamethasone",
            "dose": 40,
            "unit": "mg",
            "schedule": "PO/IV D1-4, D11-14, odd cycles"
          }
        ]
      },
      "Inotuzumab-PhNeg": {
        "name": "Inotuzumab ozogamicin (INO-VATE) (anti-CD22 ADC) (Ph- B-ALL)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Inotuzumab ozogamicin",
            "dose": 0.8,
            "unit": "mg/m²",
            "schedule": "IV D1 (0.8mg/m²), D8 (0.5mg/m²), D15 (0.5mg/m²) cycle 1; then 0.5 D1, 0.5 D8, 0.5 D15 subsequent cycles, every 21-28 days"
          }
        ]
      },
      "Blinatumomab-PhNeg": {
        "name": "Blinatumomab (TOWER) (BiTE anti-CD19) (Ph- B-ALL)",
        "cycles": 5,
        "drugs": [
          {
            "name": "Blinatumomab",
            "dose": 28,
            "unit": "µg/day",
            "schedule": "CIV D1-28 (9µg/day D1-7 cycle 1, then 28µg/day), 14 days off between cycles"
          }
        ]
      },
      "Tisagenlecleucel": {
        "name": "Tisagenlecleucel (ELIANA) (CAR-T anti-CD19) (age ≤25, B-ALL)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Tisagenlecleucel",
            "dose": 0.6,
            "unit": "× 10⁸ CAR+ T cells",
            "schedule": "Single IV infusion (0.2-5 × 10⁶/kg for <50kg, 0.1-2.5 × 10⁸ for ≥50kg)"
          }
        ]
      },
      "Brexucabtagene-Autoleucel": {
        "name": "Brexucabtagene autoleucel (ZUMA-3) (CAR-T anti-CD19) (adult B-ALL)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Brexucabtagene autoleucel",
            "dose": 1,
            "unit": "× 10⁶ CAR+ T cells/kg",
            "schedule": "Single IV infusion (max 1 × 10⁸ cells)"
          }
        ]
      },
      "Nelarabine-T-ALL": {
        "name": "Nelarabine (T-ALL/T-LBL)",
        "drugs": [
          {
            "name": "Nelarabine",
            "dose": 1500,
            "unit": "mg/m²",
            "schedule": "IV D1,3,5, every 21 days"
          }
        ]
      },
      "POMP-Maintenance": {
        "name": "POMP maintenance (6-MP + methotrexate + vincristine + prednisone)",
        "drugs": [
          {
            "name": "6-Mercaptopurine",
            "dose": 50,
            "unit": "mg/m²",
            "schedule": "PO daily continuously"
          },
          {
            "name": "Methotrexate",
            "dose": 20,
            "unit": "mg/m²",
            "schedule": "PO weekly"
          },
          {
            "name": "Vincristine",
            "dose": 2,
            "unit": "mg",
            "schedule": "IV D1, monthly"
          },
          {
            "name": "Prednisone",
            "dose": 200,
            "unit": "mg",
            "schedule": "PO daily D1-5, monthly"
          }
        ]
      }
    },
    "relapsed_refractory": {
      "Blinatumomab-RR": {
        "name": "Blinatumomab (TOWER) (BiTE anti-CD19) (R/R Ph- B-ALL)",
        "cycles": 5,
        "drugs": [
          {
            "name": "Blinatumomab",
            "dose": 28,
            "unit": "µg/day",
            "schedule": "CIV D1-28 (9µg/day D1-7 cycle 1, then 28µg/day), 14 days off between cycles"
          }
        ]
      },
      "Inotuzumab-RR": {
        "name": "Inotuzumab ozogamicin (INO-VATE) (anti-CD22 ADC) (R/R B-ALL)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Inotuzumab ozogamicin",
            "dose": 0.8,
            "unit": "mg/m²",
            "schedule": "IV D1 (0.8mg/m²), D8 (0.5mg/m²), D15 (0.5mg/m²) cycle 1; then 0.5 D1, 0.5 D8, 0.5 D15 subsequent cycles, every 21-28 days"
          }
        ]
      },
      "Tisagenlecleucel-RR": {
        "name": "Tisagenlecleucel (ELIANA) (CAR-T anti-CD19) (R/R, age ≤25)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Tisagenlecleucel",
            "dose": 0.6,
            "unit": "× 10⁸ CAR+ T cells",
            "schedule": "Single IV infusion (0.2-5 × 10⁶/kg for <50kg, 0.1-2.5 × 10⁸ for ≥50kg)"
          }
        ]
      },
      "Brexucabtagene-Autoleucel-RR": {
        "name": "Brexucabtagene autoleucel (ZUMA-3) (CAR-T anti-CD19) (R/R adult B-ALL)",
        "cycles": 1,
        "drugs": [
          {
            "name": "Brexucabtagene autoleucel",
            "dose": 1,
            "unit": "× 10⁶ CAR+ T cells/kg",
            "schedule": "Single IV infusion (max 1 × 10⁸ cells)"
          }
        ]
      },
      "Nelarabine-RR-T-ALL": {
        "name": "Nelarabine (R/R T-ALL/T-LBL)",
        "drugs": [
          {
            "name": "Nelarabine",
            "dose": 1500,
            "unit": "mg/m²",
            "schedule": "IV D1,3,5, every 21 days"
          }
        ]
      },
      "Clofarabine-RR": {
        "name": "Clofarabine (purine analog) (R/R ALL, age ≤21)",
        "cycles": 6,
        "drugs": [
          {
            "name": "Clofarabine",
            "dose": 52,
            "unit": "mg/m²",
            "schedule": "IV D1-5, every 28 days"
          }
        ]
      }
    }
  },
  "aml": {
    "primary_treatment": {
      "7plus3-Standard": {
        "name": "7+3 (standard induction) (cytarabine + daunorubicin)",
        "cycles": 2,
        "drugs": [
          {
            "name": "Cytarabine",
            "dose": 200,
            "unit": "mg/m²",
            "schedule": "CIV D1-7"
          },
          {
            "name": "Daunorubicin",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "IV D1-3"
          }
        ]
      },
      "7plus3-Idarubicin": {
        "name": "7+3 (cytarabine + idarubicin) (induction)",
        "cycles": 2,
        "drugs": [
          {
            "name": "Cytarabine",
            "dose": 200,
            "unit": "mg/m²",
            "schedule": "CIV D1-7"
          },
          {
            "name": "Idarubicin",
            "dose": 12,
            "unit": "mg/m²",
            "schedule": "IV D1-3"
          }
        ]
      },
      "7plus3-Midostaurin-FLT3": {
        "name": "7+3 + Midostaurin (RATIFY) (FLT3-mutated)",
        "cycles": 2,
        "drugs": [
          {
            "name": "Cytarabine",
            "dose": 200,
            "unit": "mg/m²",
            "schedule": "CIV D1-7"
          },
          {
            "name": "Daunorubicin",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "IV D1-3"
          },
          {
            "name": "Midostaurin",
            "dose": 50,
            "unit": "mg",
            "schedule": "PO twice daily D8-21"
          }
        ]
      },
      "CPX-351-sAML": {
        "name": "CPX-351 (Vyxeos) (therapy-related/MDS-related AML)",
        "cycles": 2,
        "drugs": [
          {
            "name": "CPX-351 (liposomal daunorubicin:cytarabine)",
            "dose": 44,
            "unit": "units/m²",
            "schedule": "IV over 90 min D1,3,5 (induction); D1,3 (consolidation)"
          }
        ]
      },
      "Azacitidine-Venetoclax": {
        "name": "Azacitidine + Venetoclax (VIALE-A) (unfit for intensive chemo)",
        "drugs": [
          {
            "name": "Azacitidine",
            "dose": 75,
            "unit": "mg/m²",
            "schedule": "SC/IV D1-7, every 28 days"
          },
          {
            "name": "Venetoclax",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily (3-day ramp-up) D1-28, every 28 days"
          }
        ]
      },
      "Decitabine-Venetoclax": {
        "name": "Decitabine + Venetoclax (unfit for intensive chemo)",
        "drugs": [
          {
            "name": "Decitabine",
            "dose": 20,
            "unit": "mg/m²",
            "schedule": "IV D1-5, every 28 days"
          },
          {
            "name": "Venetoclax",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily (3-day ramp-up) D1-28, every 28 days"
          }
        ]
      },
      "LDAC-Venetoclax": {
        "name": "Low-dose cytarabine + Venetoclax (VIALE-C) (unfit for intensive/HMA)",
        "drugs": [
          {
            "name": "Cytarabine",
            "dose": 20,
            "unit": "mg",
            "schedule": "SC twice daily D1-10, every 28 days"
          },
          {
            "name": "Venetoclax",
            "dose": 600,
            "unit": "mg",
            "schedule": "PO once daily (4-day ramp-up) D1-28, every 28 days"
          }
        ]
      },
      "Azacitidine-Monotherapy": {
        "name": "Azacitidine monotherapy (AZA-001) (unfit for intensive chemo)",
        "drugs": [
          {
            "name": "Azacitidine",
            "dose": 75,
            "unit": "mg/m²",
            "schedule": "SC/IV D1-7, every 28 days"
          }
        ]
      },
      "Decitabine-Monotherapy": {
        "name": "Decitabine monotherapy (DACO-016) (unfit for intensive chemo)",
        "drugs": [
          {
            "name": "Decitabine",
            "dose": 20,
            "unit": "mg/m²",
            "schedule": "IV D1-5, every 28 days"
          }
        ]
      },
      "Gemtuzumab-Ozogamicin-Combo": {
        "name": "Gemtuzumab ozogamicin + 7+3 (ALFA-0701) (CD33+, favorable/intermediate risk)",
        "cycles": 2,
        "drugs": [
          {
            "name": "Gemtuzumab ozogamicin",
            "dose": 3,
            "unit": "mg/m²",
            "schedule": "IV D1,4,7 (induction); D1 (consolidation)"
          },
          {
            "name": "Cytarabine",
            "dose": 200,
            "unit": "mg/m²",
            "schedule": "CIV D1-7"
          },
          {
            "name": "Daunorubicin",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "IV D1-3"
          }
        ]
      },
      "HiDAC-Consolidation": {
        "name": "High-dose cytarabine (HiDAC) (consolidation)",
        "cycles": 4,
        "drugs": [
          {
            "name": "Cytarabine",
            "dose": 3000,
            "unit": "mg/m²",
            "schedule": "IV over 3h q12h D1,3,5 (6 doses per cycle), every 28 days"
          }
        ]
      },
      "ATRA-ATO-APL": {
        "name": "ATRA + Arsenic trioxide (Lo-Coco) (APL, low-intermediate risk)",
        "drugs": [
          {
            "name": "All-trans retinoic acid (ATRA)",
            "dose": 45,
            "unit": "mg/m²",
            "schedule": "PO daily in 2 divided doses until CR"
          },
          {
            "name": "Arsenic trioxide",
            "dose": 0.15,
            "unit": "mg/kg",
            "schedule": "IV daily until CR (induction), then 5 days/week 4 weeks on/4 weeks off x 4 (consolidation)"
          }
        ]
      },
      "ATRA-Idarubicin-APL": {
        "name": "ATRA + Idarubicin (AIDA) (APL, high risk)",
        "drugs": [
          {
            "name": "All-trans retinoic acid (ATRA)",
            "dose": 45,
            "unit": "mg/m²",
            "schedule": "PO daily in 2 divided doses until CR"
          },
          {
            "name": "Idarubicin",
            "dose": 12,
            "unit": "mg/m²",
            "schedule": "IV D2,4,6,8 (induction)"
          }
        ]
      },
      "Midostaurin-Maintenance-FLT3": {
        "name": "Midostaurin maintenance (RATIFY) (FLT3-mutated, post-consolidation)",
        "drugs": [
          {
            "name": "Midostaurin",
            "dose": 50,
            "unit": "mg",
            "schedule": "PO twice daily continuously for 12 months"
          }
        ]
      },
      "Azacitidine-Maintenance-CC-486": {
        "name": "Oral azacitidine maintenance (QUAZAR AML-001) (CR1, unfit for transplant)",
        "drugs": [
          {
            "name": "Oral azacitidine (CC-486)",
            "dose": 300,
            "unit": "mg",
            "schedule": "PO once daily D1-14, every 28 days"
          }
        ]
      },
      "Ivosidenib-IDH1": {
        "name": "Ivosidenib (AGILE) (IDH1-mutated) (monotherapy or + azacitidine)",
        "drugs": [
          {
            "name": "Ivosidenib",
            "dose": 500,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Enasidenib-IDH2": {
        "name": "Enasidenib (AG221-001) (IDH2-mutated)",
        "drugs": [
          {
            "name": "Enasidenib",
            "dose": 100,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Ivosidenib-Azacitidine-IDH1": {
        "name": "Ivosidenib + Azacitidine (AGILE) (IDH1-mutated, unfit for intensive)",
        "drugs": [
          {
            "name": "Ivosidenib",
            "dose": 500,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          },
          {
            "name": "Azacitidine",
            "dose": 75,
            "unit": "mg/m²",
            "schedule": "SC/IV D1-7, every 28 days"
          }
        ]
      },
      "Olutasidenib-IDH1": {
        "name": "Olutasidenib (IDH1 inhibitor) (R/R IDH1-mutated)",
        "drugs": [
          {
            "name": "Olutasidenib",
            "dose": 150,
            "unit": "mg",
            "schedule": "PO twice daily continuously"
          }
        ]
      },
      "Quizartinib-FLT3-ITD": {
        "name": "Quizartinib + 7+3 (QuANTUM-First) (FLT3-ITD)",
        "cycles": 2,
        "drugs": [
          {
            "name": "Quizartinib",
            "dose": 40,
            "unit": "mg",
            "schedule": "PO once daily D8-21 (induction/consolidation), then continuously (maintenance)"
          },
          {
            "name": "Cytarabine",
            "dose": 200,
            "unit": "mg/m²",
            "schedule": "CIV D1-7"
          },
          {
            "name": "Daunorubicin",
            "dose": 60,
            "unit": "mg/m²",
            "schedule": "IV D1-3"
          }
        ]
      }
    },
    "relapsed_refractory": {
      "Gilteritinib-FLT3": {
        "name": "Gilteritinib (ADMIRAL) (FLT3-mutated R/R AML)",
        "drugs": [
          {
            "name": "Gilteritinib",
            "dose": 120,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Venetoclax-Azacitidine-RR": {
        "name": "Venetoclax + Azacitidine (BCL-2 + HMA) (R/R AML)",
        "drugs": [
          {
            "name": "Venetoclax",
            "dose": 400,
            "unit": "mg",
            "schedule": "PO once daily (3-day ramp-up) D1-28, every 28 days"
          },
          {
            "name": "Azacitidine",
            "dose": 75,
            "unit": "mg/m²",
            "schedule": "SC/IV D1-7, every 28 days"
          }
        ]
      },
      "MEC": {
        "name": "MEC (mitoxantrone + etoposide + cytarabine) (R/R AML)",
        "cycles": 2,
        "drugs": [
          {
            "name": "Mitoxantrone",
            "dose": 8,
            "unit": "mg/m²",
            "schedule": "IV D1-5"
          },
          {
            "name": "Etoposide",
            "dose": 100,
            "unit": "mg/m²",
            "schedule": "IV D1-5"
          },
          {
            "name": "Cytarabine",
            "dose": 1000,
            "unit": "mg/m²",
            "schedule": "IV D1-5"
          }
        ]
      },
      "FLAG-IDA": {
        "name": "FLAG-IDA (fludarabine + cytarabine + G-CSF + idarubicin) (R/R AML)",
        "cycles": 2,
        "drugs": [
          {
            "name": "Fludarabine",
            "dose": 30,
            "unit": "mg/m²",
            "schedule": "IV D1-5"
          },
          {
            "name": "Cytarabine",
            "dose": 2000,
            "unit": "mg/m²",
            "schedule": "IV D1-5 (4 hours after fludarabine)"
          },
          {
            "name": "Idarubicin",
            "dose": 10,
            "unit": "mg/m²",
            "schedule": "IV D1-3"
          }
        ]
      },
      "CLAG-M": {
        "name": "CLAG-M (cladribine + cytarabine + G-CSF + mitoxantrone) (R/R AML)",
        "cycles": 2,
        "drugs": [
          {
            "name": "Cladribine",
            "dose": 5,
            "unit": "mg/m²",
            "schedule": "IV D1-5"
          },
          {
            "name": "Cytarabine",
            "dose": 2000,
            "unit": "mg/m²",
            "schedule": "IV D1-5"
          },
          {
            "name": "Mitoxantrone",
            "dose": 10,
            "unit": "mg/m²",
            "schedule": "IV D1-3"
          }
        ]
      },
      "Gemtuzumab-Ozogamicin-Mono-RR": {
        "name": "Gemtuzumab ozogamicin monotherapy (CD33+ R/R AML)",
        "drugs": [
          {
            "name": "Gemtuzumab ozogamicin",
            "dose": 3,
            "unit": "mg/m²",
            "schedule": "IV D1,4,7, every 28 days"
          }
        ]
      },
      "Ivosidenib-RR-IDH1": {
        "name": "Ivosidenib (IDH1-mutated R/R AML)",
        "drugs": [
          {
            "name": "Ivosidenib",
            "dose": 500,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Enasidenib-RR-IDH2": {
        "name": "Enasidenib (AG221-001) (IDH2-mutated R/R AML)",
        "drugs": [
          {
            "name": "Enasidenib",
            "dose": 100,
            "unit": "mg",
            "schedule": "PO once daily continuously"
          }
        ]
      },
      "Revumenib-KMT2A": {
        "name": "Revumenib (AUGMENT-101) (menin inhibitor) (KMT2A-rearranged/NPM1-mutated R/R AML)",
        "drugs": [
          {
            "name": "Revumenib",
            "dose": 163,
            "unit": "mg",
            "schedule": "PO twice daily continuously"
          }
        ]
      },
      "Olutasidenib-RR-IDH1": {
        "name": "Olutasidenib (IDH1 inhibitor) (R/R IDH1-mutated AML)",
        "drugs": [
          {
            "name": "Olutasidenib",
            "dose": 150,
            "unit": "mg",
            "schedule": "PO twice daily continuously"
          }
        ]
      }
    }
  }
};
